Please upgrade your browser.
Spring 2011 edition is online.
tthe first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).
As early as 1932, physicians noticed an apparent association between type 2 diabetes and increased cancer risk. In recent years, the epidemiological evidence of such an association has mounted steadilyespecially with the emergence of large databases, which have allowed us to document the link.
A Phase I Study of Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Metastatic Melanoma and Metastatic Renal Cell Cancer
Renal cell cancer patients must either have refused treatment with, have been unable to tolerate, or have experienced progressive disease after treatment with sorafenib or sunitinib and temsirolimus...
A new study by McKinsey suggests that as many as 78 million Americans could lose employer health coverage.
Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma.
This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.
"These data, from the first head-to-head phase III study comparing active targeted therapies in advanced RCC, are important for clinicians as they help us advance our understanding of this tumor, where there are limited proven options for previously treated patients," said principal investigator Brian I. Rini, M.D.
Among 25 RCC patients treated at escalating doses of SGN-75, two patients achieved a partial response, eight patients had stable disease...
Though just five to six drugs are presently approved, there are many others in the pipeline, including targeted therapies that are expected to make kidney cancer market an active ground for competition in the future.
|Powered by NeonCRM|